1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Galderma Hopes To Break Into Prurigo Nodularis Market, But May Face Rivals

 
• By Alaric DeArment

The dermatology specialist announced positive results from the OLYMPIA 2 trial of nemolizumab, but Sanofi and Regeneron are already pursuing a similar indication for Dupixent. 

Galderma announced results from the Phase III OLYMPIA 2 trial of nemolizumab in prurigo nodularis • Source: Shutterstock

The Swiss dermatology company Galderma S.A. is looking to edge into a niche market for the rare disease prurigo nodularis with nemolizumab, but the company could have to face big pharma rivals in the space. Regeneron Pharmaceuticals, Inc. and Sanofi are roughly three months out from securing another potential indication for their blockbuster autoimmune disease drug Dupixent (dupilumab) for the treatment of prurigo nodularis from the US Food and Drug Administration.

Dupixent is a blockbuster drug marketed by two large pharmaceutical companies, while Galderma is an experienced dermatology player but with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 
• By Jessica Merrill

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

More from R&D

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

Pipeline-In-A-Product: A Retrospective On The Development Of Dupixent

 
• By Jessica Merrill, Kevin Grogan, and Edwin Elmhirst

Dupixent’s success across eight indications is a model other drugmakers would like to replicate. R&D leaders at Sanofi and Regeneron reflect back on the development strategy that built the $15bn product.